Fig 1: Integrative multiomic study in hepatocytes with PKLR perturbation. (a) Integrative transcriptomic and nontargeted metabolomic analysis identified the variations on pathways of linoleic acid metabolism in hepatocytes with overexpressed PKLR. (b) Integrative transcriptomic and nontargeted metabolomic analysis identified the variations on pathways of linoleic acid metabolism in hepatocytes with downregulated PKLR. (c) Integrative transcriptomic and nontargeted metabolomic analysis identified the variations on pathways of glycerophospholipid metabolism in hepatocytes with overexpressed PKLR. (d) Integrative transcriptomic and nontargeted metabolomic analysis identified the variations on pathways of glycerophospholipid metabolism in hepatocytes with downregulated PKLR. (e) Integrative transcriptomic and targeted metabolomic analysis identified the variations on pathways of glycolysis in hepatocytes with overexpressed PKLR. (f) Integrative transcriptomic and targeted metabolomic analysis identified the variations on pathways of glycolysis in hepatocytes with downregulated PKLR. (g) Integrative transcriptomic and targeted metabolomic analysis identified the variations on pathways of citrate cycle in hepatocytes with overexpressed PKLR. (h) Integrative transcriptomic and targeted metabolomic analysis identified the variations on pathways of citrate cycle in hepatocytes with downregulated PKLR. (i) Integrative transcriptomic and targeted metabolomic analysis identified the variations on pathways of arginine biosynthesis in hepatocytes with overexpressed PKLR. (j) Integrative transcriptomic and targeted metabolomic analysis identified the variations on pathways of arginine biosynthesis in hepatocytes with downregulated PKLR. (k) Integrative transcriptomic and targeted metabolomic analysis identified the variations on pathways of pyruvate metabolism in hepatocytes with overexpressed PKLR. (l) Integrative transcriptomic and targeted metabolomic analysis identified the variations on pathways of pyruvate metabolism in hepatocytes with downregulated PKLR. (m) Integrative transcriptomic and targeted metabolomic analysis identified the variations on pathways of butanoate metabolism in hepatocytes with overexpressed PKLR. (n) Integrative transcriptomic and targeted metabolomic analysis identified the variations on pathways of butanoate metabolism in hepatocytes with downregulated PKLR. (o) Network connection for variations of key metabolites from targeted metabolomics in hepatocytes with overexpressed PKLR. In (a–n), the frame in rectangle represented the genes involved in pathways; the frame in ellipse or circle represented the metabolites involved in pathways. In (o), the frame in green represented downregulation, and the frame in red represented upregulation in cells with PKLR overexpression.
Fig 2: Genetic impact of pyruvate kinase L/R on the process of de novo lipogenesis. HepG2 cells with PKLR alteration were treated by high-glucose medium (50 mmol/L), respectively, for 48 hours. And lipogenic severity was evaluated by ORO staining. (a) ORO staining for cells with overexpressed PKLR. (b) ORO staining for NC cells with overexpressed PKLR. (c) ORO staining for cells with suppressed PKLR. (d) ORO staining for NC cells with suppressed PKLR. (e) Comparison of lipogenic severity between cells with overexpressed/suppressed PKLR and their corresponded NC. (f) Comparison of hepatic TG between cells with overexpressed/suppressed PKLR and their corresponded NC. (g) Comparison of hepatic TC between cells with overexpressed/suppressed PKLR and their corresponded NC. (h) Comparison of key genes that located on DNL process between cells with overexpressed PKLR and their corresponded NC. (i) Comparison of key genes that located on DNL process between cells with suppressed PKLR and their corresponded NC. (j) PPI network between PKLR and selected genes that located on DNL process. (k) Speculated mechanism for the impact of PKLR on DNL process. Stained cells were observed and scanned under a microscope (magnification: 400x); ∗ represented statistical significance for comparisons between targeted cells and corresponded NC (P < 0.05); TG and TC were both evaluated in systems with 100 000 cells in 100 μL of solution buffer. Frames in red represented the molecules with upregulations; frames in blue represented the molecules with downregulations. Abbreviations: a-KG: alpha-ketoglutarate; DNL: de novo lipogenesis; G-6-P: glucose-6-phosphate; ORO: oil red O; NC: negative control; OAA: oxaloacetate; PEP: phosphoenolpyruvate; PC: phosphatidylinositol; PKLR: pyruvate kinase L/R; PPI: protein-protein interaction; TCA: tricarboxylic acid cycle; TC: total cholesterol; TG: triglyceride.
Fig 3: Comprehensive analysis on nontargeted metabolomic results in grafts for transplantation classified by PK variations. (a) Heatmap for correlation between interconnection between PKLR/PKM genes and clinical factors in LT; frame in ∗ represented the correlation with statistical significance (P < 0.05). (b) Correlation analysis between log-transformed PKLR and PKM expression in grafts for LT. (c) Analysis on grafts' survival categorized by PKLR/PKM expression. (d) Analysis on patients' survival categorized by PKLR/PKM expression. (e) Distribution of EAD occurrence in patients categorized by PKLR/PKM expression. (f) Distribution of PNF occurrence in patients categorized by PKLR/PKM expression. (g) PCA in patients categorized by PKLR expression, dots in blue represented the samples with higher PKLR, and the dots in green represented the samples with lower PKLR. (h) Heatmap for clusters of metabolites significantly associated with PKLR expression. (i) Volcano plot on visualization of both FC and significance for each metabolite compared between higher and lower PKLR expression, red dots represented significantly higher metabolites (FC > 2, P < 0.05) in grafts with higher PKLR, and green dots represented significantly lower metabolites (FC < 0.5, P < 0.05) in grafts with higher PKLR. (j) Correlation heatmap for the top 20 metabolites associated with PKLR expression. (k) Overlap between significant metabolites in cells and grafts by KEGG identification. (l) FC of C00157 and C04230 categorized by PKM/PKLR expression. (m) Scatter plot for correlation between log-transformed PKLR and C00157 expression. (n) Scatter plot for correlation between log-transformed PKLR and C04230 expression. (o) Scatter plot for correlation between log-transformed PKM and C00157 expression. (p) Scatter plot for correlation between log-transformed PKM and C04230 expression. Abbreviations: EAD: early allograft dysfunction; FC: fold change; LT: liver transplantation; PCA: principal component analysis; PNF: primary nonfunction.
Fig 4: Weighted correlation network analysis on nontargeted metabolome of grafts and its connections with clinical factors. (a) Cluster dendrogram obtained by dissimilarity based on consensus topological overlap with the corresponding modules indicated by the color row. Each colored row represented a color-coded module containing a group of highly connected metabolites. (b) Relationships of consensus module and clinical features of LT cases. Each row in the table corresponded to a consensus module, and each column corresponded to a feature. The module name was shown on the left side for each cell. Numbers in the table reported the correlations of the corresponded module and feature, with the P values printed below. The table is color coded by correlation according to the color legend. Intensity and direction of correlations are indicated on the right side of the heatmap. (c) Dendrogram of consensus module and heatmap of the adjacencies obtained by WGCNA on the consensus correlation. Numbers in the table reported the intermodule correlations, with the P values printed below. The table was color coded by correlation according to the color legend indicated on the right side of the heatmap. (d) Scatterplot of metabolite significance PKLR vs. MM in the green module. (e) Results for pathway enrichment based on metabolites in the green module. (f) Details of arachidonic acid metabolism and related metabolites involved in module. (g) Scatterplot of metabolite significance PKLR vs. MM in the brown module. (h) Scatterplot of metabolite significance PKLR vs. MM in the turquoise module. (i) Coexpression network by top 20 nodes based on coexpressed links in positive metabolites from nontargeted metabolomics of hepatocytes. (j) Coexpression network by top 10 nodes based on coexpressed links in positive metabolites from nontargeted metabolomics of human grafts for transplantation. (k) Coexpression network centered by C00157 and C04230 based on coexpressed links from nontargeted metabolomics of hepatocytes. (l) Coexpression network centered by C00157 and C04230 based on coexpressed links from nontargeted metabolomics of grafts for transplantation. Abbreviations: LT: liver transplantation; MM: module membership.
Fig 5: Comprehensive analysis on targeted metabolomic results in cells with PKLR variations. (a) PCA revealed clear separation in targeted metabolomic data from hepatocytes with overexpressed PKLR (OV), dots in green [2] represented the samples with overexpressed PKLR, and dots in blue [1] represented the corresponded NC samples. (b) Validation of OPLS-DA model by class permutation analysis for (a). (c) PCA revealed clear separation in targeted metabolomic data from hepatocytes with downregulated PKLR (SI), dots in green [2] represented the samples with downregulated PKLR, and dots in blue [1] represented the corresponded NC samples. (d) Validation of OPLS-DA model by class permutation analysis for (c). (e) Heatmap for comparison between samples from OV group and corresponded NC in all enrolled metabolites. (f) Heatmap for comparison between samples from SI group and corresponded NC in all enrolled metabolites. (g) Heatmap for comparison between samples from OV and SI groups in all enrolled metabolites. (h) Correlations on log-transformed FCs of each metabolite from OV and SI groups. (i) Overlapped positive metabolites compared in (f)/(g)/(h). (j) Correlation heatmap for all enrolled metabolites from targeted metabolomics; the table is color coded by correlation according to the color legend; legend on intensity and direction of correlations is indicated on the right side of the heatmap. (k) Correlation heatmap for positive metabolites from targeted metabolomics that are associated with PKLR variations; the table is color coded by correlation according to the color legend; legend on intensity and direction of correlations is indicated on the right side of the heatmap. (l) Details on variations of positive metabolites in different comparisons categorized by PKLR expression (OV vs. NC/SI vs. NC/OV vs. SI); # represented insignificant FC in comparison. (m) Rank of pathways based on positive metabolites from targeted metabolomics by enrichment ratios. (n) Pathway analysis based on positive metabolites from targeted metabolomics that are associated with PKLR expression. (o) Details of pathway on TCA cycle and positive metabolites that are associated with PKLR expression. (p) Details of pathway on pyruvate metabolism and positive metabolites that are associated with PKLR expression. (q) Venn plot for those overlapped across the positive metabolites from pathways A (TCA cycle), B (pyruvate metabolism), and C (glycolysis). (r) PEP-to-pyruvate ratio presented in different comparisons (OV vs. NC/SI vs. NC). (s) ATP-to-ADP ratio presented in different comparisons (OV vs. NC/SI vs. NC). (t) NADPH-to-NADP+ ratio presented in different comparisons (OV vs. NC/SI vs. NC). Abbreviations: FC: fold change; NC: negative control; OV: overexpression; PCA: principal component analysis; PEP: phosphoenolpyruvate; SI: silence; TCA: tricarboxylic acid cycle.
Supplier Page from OriGene Technologies for Pyruvate Kinase (PKLR) Human shRNA Lentiviral Particle (Locus ID 5313)